Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shire
Manufacturing
Takeda is calling it quits on Natpara's US commercial return
Takeda has elected to nix all manufacturing of its Natpara injection for hypoparathyroidism in the U.S. and abroad by the end of 2024.
Fraiser Kansteiner
Oct 4, 2022 2:35pm
Novo Nordisk's semaglutide misses the mark in NASH study
Jun 29, 2022 10:53am
Takeda CEO Weber says pandemic, war could lower drug prices
Jun 2, 2022 7:42am
Takeda taps doctor turned patient for rare disease campaign
Feb 4, 2022 8:24am
AstraZeneca, Takeda, Biogen, Samsung and more—Fierce Pharma Asia
Feb 4, 2022 6:26am
AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit
Sep 14, 2021 4:00pm
